Loading stock data…
Context Therapeutics Inc (CNTX)
$0.58-0.00 (-0.50%)
Market ClosedLast close Jun 29
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Context Therapeutics Inc. in the Healthcare sector is trading at $0.58 with a market capitalization of $59M. Wall Street consensus targets $5.38 (8 analysts), implying a +831.4% move over the next 12 months. The stock is currently near its 52-week low of $0.55, remaining 67.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 6 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +831.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 6) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.34M↑ | -$13.80M↓ | -$10.61M↓ | -$9.76M↓ | -$5.53M |
| Net Income | -$8.68M↑ | -$13.03M↓ | -$9.69M↓ | -$8.83M↓ | -$4.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-77.06%
Volume
Today's trading volume
3.50M
Recent News
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip
The Philadelphia biotech reported data from 21 patients with advanced CLDN6-positive solid tumors, including 14 with platinum-resistant ovarian cancer.
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLDN6 x CD3 T-cell engaging bispecific antibody, showing early signs of efficacy and a favorable safety profile in patients with advanced, late-line platinum-resistant ovarian cancer. The data, based on a May 29, 2026, cutoff from the ongoing Phase 1 study, included 21 patients across ovarian, testicular, and endometrial cancers who received weekly doses ranging from 22.5 micrograms to 560 micrograms
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data
Context Therapeutics (NASDAQ:CNTX) is focused on developing T-cell engager (TCE) therapies for solid tumors, with an emphasis on addressing resistance that can emerge after antibody-drug conjugate (ADC) treatment, company Chief Executive Officer Martin Lehr said during a fireside chat at Leerink Par
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr outlined the company’s strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell engager (TCE) antibodies for solid tumors. Lehr described TCEs as anti